Author: Mrinalika Roy
-
Exxon shareholders soundly reject all climate-related petitions
By Sabrina Valle and Mrinalika Roy HOUSTON (Reuters) – Exxon Mobil Corp. shareholders on Wednesday overwhelmingly supported the company’s views on climate reports and strategies, rejecting proposals for report on methane, greenhouse gas reporting and oil-spill preparations by a wide margin. None of the initiative proposals received more than 36% of votes cast, according to…
-

Walgreens weathers slowing COVID vaccination with higher retail sales
By Mrinalika Roy and Raghav Mahobe (Reuters) – Walgreens Boots Alliance Inc reported a better-than-expected quarterly profit on Thursday, as higher UK retail sales helped more than offset waning COVID vaccination demand. Shares of Walgreens, one of the largest U.S. pharmacies, rose nearly 3% amid bigger market weakness after the company also forecast a “better-than-feared”…
-
Cigna boosts forecast as lower costs drive profit beat
By Mrinalika Roy and Bhanvi Satija (Reuters) -Cigna Corp on Thursday raised its annual earnings forecast after topping quarterly profit estimates as a slow recovery in non-urgent procedures lowers medical expenses, sending the insurer’s shares up about 5%. Cigna’s robust performance rounded off a strong quarter for health insurers that have seen their fortunes fluctuate…
-
Walgreens keeps forecast as waning COVID vaccine demand weighs
By Mrinalika Roy and Leroy Leo (Reuters) -Walgreens Boots Alliance Inc on Thursday maintained its full-year earnings forecast due to declining COVID vaccinations, even as the drugstore retailer beat quarterly estimates on the back of strength in its UK-based Boots business. Shares of the second-biggest U.S. drugstore retailer by store count fell 4% to $39.14…
-
CVS Health raises annual profit view after better-than-expected first quarter
By Mrinalika Roy (Reuters) -CVS Health Corp beat estimates for first-quarter results on Wednesday, helped by strong performance in its retail store operations and insurance unit, encouraging the company to raise annual adjusted profit forecast. Pharmacy chains like CVS have benefited from distribution of COVID-19 vaccines and tests during the pandemic. However, in February, the…
-
Biogen CEO to step down; drugmaker pulls back on Alzheimer’s drug Aduhelm
By Mrinalika Roy and Leroy Leo (Reuters) – Biogen Inc said on Tuesday that Chief Executive Michel Vounatsos will step down and that the company is pulling back on selling its Alzheimer’s drug Aduhelm after the U.S. government’s Medicare program restricted coverage of the controversial treatment to patients in clinical trials. Vounatsos, who was named…





